Therefore, given the impact of glutamine metabolism on tumor immune response and the significant role of AST and ALT in this process, our aim is to explore the relationship between the easily accessible hematological marker AST/ALT ratio and the prognosis of non-small cell lung cancer patients receiving ICIs-nonRT and iRT, to aid in more precise clinical treatment. This evidence concerns the gene GPT and non-small cell lung carcinoma.